MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on May 25, 2006; DOI: 10.1124/mol.106.027078

0026-895X/06/7002-440-443$20.00
Mol Pharmacol 70:440-443, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Related Article
Right arrow All Versions of this Article:
mol.106.027078v1
70/2/440    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Newton, S. S.
Right arrow Articles by Duman, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Newton, S. S.
Right arrow Articles by Duman, R. S.
Perspective

Chromatin Remodeling: A Novel Mechanism of Psychotropic Drug Action

Samuel S. Newton, and Ronald S. Duman

Laboratory of Molecular Psychiatry, Departments of Psychiatry and Pharmacology, Yale University School of Medicine, New Haven, Connecticut

Regulation of gene expression is known to contribute to the long-term adaptations underlying the effects of psychotropic drugs, including the actions of antidepressants and drugs of abuse in behavioral models. However, the precise molecular events that are required for modification of chromatin and that underlie gene repression or activation have not been elucidated. Recent reports, including the article by Cassel et al. (p. 487) in this issue of Molecular Pharmacology, address this question and demonstrate that psychotropic drugs modify specific methyl-CpG-binding proteins that control histone acetylation and gene expression.

Received May 23, 2006; accepted May 25, 2006

Address correspondence to: Dr. Ronald S. Duman, 34 Park St, New Haven, CT 06508. E-mail: ronald.duman{at}yale.edu


Related articles in MolPharm:

Fluoxetine and Cocaine Induce the Epigenetic Factors MeCP2 and MBD1 in Adult Rat Brain
Suzanne Cassel, Delphine Carouge, Claire Gensburger, Patrick Anglard, Claude Burgun, Jean-Bernard Dietrich, Dominique Aunis, and Jean Zwiller
MolPharm 2006 70: 487-492. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 J. Neurosci.Home page
P. Romieu, L. Host, S. Gobaille, G. Sandner, D. Aunis, and J. Zwiller
Histone Deacetylase Inhibitors Decrease Cocaine But Not Sucrose Self-Administration in Rats
J. Neurosci., September 17, 2008; 28(38): 9342 - 9348.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
S. C. Pandey, R. Ugale, H. Zhang, L. Tang, and A. Prakash
Brain Chromatin Remodeling: A Novel Mechanism of Alcoholism
J. Neurosci., April 2, 2008; 28(14): 3729 - 3737.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics